Objectives To estimate the cost effectiveness of rivaroxaban compared to warfarin for the
prophylaxis of stroke in patients with atrial fibrillation (AF) from a payer perspective in …

Objectives To assess the cost-effectiveness of rivaroxaban versus acenocumarol and a real-
world prescription pattern (RWP), for prevention of stroke in atrial fibrillation (AF) patients in …

Objectives To undertake an economic evaluation of rivaroxaban relative to the local
standard of care, acenocoumarol, for stroke prevention in atrial fibrillation (AF) patients with …

Objectives To assess the cost-effectiveness of the novel fixed-dose anticogulant,
rivaroxaban, in comparisson to the current dose-volatile standard of care, warfarin, for the …

Objectives To evaluate the cost-effectiveness of the once daily oral anticoagulant
rivaroxaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation …

Background To undertake an economic evaluation of rivaroxaban relative to the standard of
care for stroke prevention in patients with non-valvular atrial fibrillation (AF) in Greece …

Objective The aim of this study was to assess the cost effectiveness of the novel fixed-dose
anticoagulant rivaroxaban compared with the current standard of care, warfarin, for the …

Background: Patients with non-valvular atrial fibrillation (NVAF) have a five times higher
stroke risk. For more than 50 years, vitamin K antagonists (VKAs) have been the primary …

Objectives Reference clinical guidelines recommend non-VKA anticoagulants (NOACs) over
vitamin K antagonists (VKA) for preventing stroke and systemic embolism in Nonvalvular …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …